QuidelOrtho Stock Overview After Recent Moves
QuidelOrtho (QDEL) has drawn fresh attention after recent trading, with shares last closing at $17.25. Over the past month the stock shows a return of about a 17% decline and about a 43% decline over the past 3 months.
For investors tracking performance, the stock reflects about a 40% decline year to date and about a 39% decline over the past year, with a longer term 3-year total return of about an 81% decline.
QuidelOrtho reports annual revenue of about US$2.73b from its diagnostic testing solutions, while reporting a loss of about US$1.13b on a net income basis. The company carries a value score of 5 in the provided data set.
Most of its revenue is grouped under Diagnostic Kits / Equipment, with geographic exposure spread across North America, EMEA, JPAC, China, and Latin America. North America accounts for about US$1.49b, with other regions contributing the balance of sales.
- North America: about US$1.49b in revenue
- EMEA: about US$361m
- China: about US$335m
- JPAC: about US$293m
- Latin America: about US$253m
The latest figures also show annual revenue growth of about 3% and net income growth described as a very large increase relative to the prior period, although net income remains in loss territory.
See our latest analysis for QuidelOrtho.
The recent 16.7% 7 day share price return sits against a weaker picture, with a 30 day share price return of about a 17% decline and a 1 year total shareholder return of about a 39% decline. This suggests short term momentum following a prolonged drawdown.
If you are reassessing your healthcare exposure after QuidelOrtho's moves, this could be a moment to broaden your watchlist with focused ideas from the 36 healthcare AI stocks
With the share price under pressure, a reported loss of about US$1.13b, and an indicated intrinsic discount of about 79%, you have to ask: is this a reset level offering upside, or is the market already pricing in future growth?
Most Popular Narrative: 50.2% Undervalued
QuidelOrtho's most followed narrative places fair value at about $34.67 per share versus the last close at $17.25, framing a wide valuation gap that rests heavily on long term diagnostics demand and execution on new platforms.
Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
Curious how that expansion story turns into a specific fair value per share? The narrative leans on measured revenue growth, margin repair, and a future earnings multiple that differs meaningfully from today. The key tension is how quickly those margins shift out of loss making territory and what kind of earnings power the diagnostics portfolio can support over time.
Result: Fair Value of $34.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh lingering COVID testing headwinds, as well as the risk that China reimbursement changes and competition keep pressure on pricing and margins.
Find out about the key risks to this QuidelOrtho narrative.
Next Steps
The mix of risks and rewards around QuidelOrtho is clear. If you want to move quickly and shape your own view, start by weighing the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If QuidelOrtho has sharpened your focus on risk, reward, and valuation, do not stop here. Use targeted tools to surface other opportunities that fit your style.
- Spot potential value plays early by scanning 58 high quality undervalued stocks that pair quality fundamentals with pricing that may not fully reflect their metrics.
- Prioritise staying power by reviewing the solid balance sheet and fundamentals stocks screener (40 results) so you can narrow in on companies with financial structures that may handle tougher conditions.
- Stay ahead of the crowd by tracking the screener containing 25 high quality undiscovered gems before attention and fresh capital potentially shift toward them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com